Skip to main content
Preview

Research from Friday’s close · next update overnight after Monday’s close

Radar
ABT

ABT Research brief

Abbott Laboratories

Adjusted close as of 2026-10-30
$106.20(+1.56%)

Sagehood’s view on ABT

Abbott Laboratories · Research 2026-10-30 · Accepted

Research score

52Neutral50 is balancedScore unchanged since 2026-10-29 at 52; view unchanged at Neutral. Compare the two recordsConfidence 49 · It is not a calibrated probability of investment success.Confidence across the 100 names in this research run: 45 to 70, median 55.
How to read this score

Dated research brief

WhyAbbott's steady cash conversion and 90-day recovery support a neutral view, because $7,378 million of free cash flow converts 1.18 of net income. The unresolved risk is the −16.7% drawdown, which sits near the 15-25% band while the name lags its sector.
What argues against this viewThe strongest case against the neutral stance is that the recovery and cash quality could keep improving.
Break conditionFrom the financial specialist: A later reading showing trailing-twelve-month free cash flow conversion below the 1.17 sector free-cash-flow-conversion median would break the cash-quality claim.Tests that specialist’s reading, not this page’s whole Neutral view.

Sagehood does not check this condition automatically. See research limitations below.

A newer 10-Q (filed 2026-07-28) is on record; some figures here may predate it.

Valuation range

No model fair value for this run

No fair-value range was computed for this run: the cash-flow valuation grid was unavailable because free cash flow or share data was missing.

Score details & research limitations10 unavailable fields
Conditions Sagehood can check on its ownNot available in this run. A written break condition is not an automated check; this run does not provide a source-linked rule Sagehood can verify on its own.

Where the break condition comes from: Sagehood research took this condition from the financial specialist. It tests that specialist’s own reading, so it does not say everything that would change this page’s Neutral view.

How to read this research

The score expresses the published research view. 50 is balanced.

Bullish, Neutral or Bearish beside the score is the direction of that view, set by the research from the score: 65 and above is Bullish, 45 to 64 Neutral, 44 and below Bearish.

Confidence is how well the evidence supports this view, not which way it points: Sagehood research is asked to keep it no higher than its most confident specialist, and lower when the specialists disagree or much of the evidence is weak. It is not a calibrated probability of investment success.

Source verification checks the identity and origin of evidence. It does not prove that a claim is correct or that an investment will succeed.

Valuation estimates depend on their inputs and assumptions. They are not guaranteed future prices.

Retrospective research looks back at an earlier period. It is not a verified record of a decision made then using only information available then.

Unavailable is not zero. Read the adjacent reason: information may be missing, unverified or deliberately withheld.

How Sagehood works

The session this view is fixed to

Close$106.20 on 2026-10-30, as the research recorded it
Change on the day+1.56%
First eligible market session2026-11-02

Recorded score context

Specialist source coverage8 of 10 specialists have a verified source on this run. 2 do not.
Score reconciliationThe 8 specialist contributions shown add up to the weighted starting point this score was built from.
Change since the last accepted run52 on 2026-10-29 → 52 on 2026-10-30 (0 points). This is simple arithmetic between the two published scores, not an explanation of the change.
The run this is compared withResearch of 2026-10-29

Not in this run: Run-specific score definition, Confidence band, Horizon, Why the score changed, Today's unexplained move and Blockers.

What this was built from

Filing cited in the evidenceNot recorded on this card. The newest filing on record is under Key financials, and recent filings are listed under SEC filings.

Not in this run: Company profile date, Peer set and Standing disclosure.

Not available in this run

10 fields are unavailable. Each is identified with its reason above; missing information is not zero or a negative research signal.

Price context

· adjusted close $106.20

+15.4% from 2026-06-25

Recent price-basis check: 2026-10-02 to 2026-10-30 (20 sessions). Economic comparability outside this window remains unchecked.

ABT adjusted close
Adjusted price · USD · viewing 2026-06-25 to 2026-10-30

Selected 2026-10-30. ABT adjusted close. Continuous series. $106.20 US dollars.

90 daily adjusted-price observations through 2026-10-30, ending at the 2026-10-30 research date. The final point is a dated final close. Shown for context, not point-in-time research evidence: the research used the prices recorded with it.

Use the arrow keys on the chart to step through observations.

Published score history

2026-07-23 to 2026-10-30 · 37 publications

Each point is a verified published score. The line breaks where the research method changed (4 methods, numbered in the order they were first used), so scores are not joined across methods. Hollow points were published after their decision window (retrospective).

Every published score and confidence
Research dateScoreViewConfidenceMethod
2026-10-3052Neutral49Method 4
2026-10-2952Neutral55Method 4
2026-10-2849Neutral49Method 4
2026-10-2749Neutral45Method 4
2026-10-2650Neutral49Method 4
2026-10-2350Neutral49Method 4
2026-10-2250Neutral55Method 4
2026-10-2148Neutral45Method 4
2026-10-1653Neutral55Method 4
2026-10-0949Neutral45Method 4
2026-10-0746Neutral55Method 4
2026-10-0243Bearish60Method 4
2026-10-0143Bearish60Method 4
2026-09-3047Neutral48Method 4
2026-09-2947Neutral45Method 4
2026-09-2850Neutral30Method 4
2026-09-2546Neutral55Method 4
2026-09-24 · retrospective44Bearish60Method 4
2026-09-2346Neutral60Method 4
2026-09-1847Neutral68Method 4
2026-09-16 · retrospective44Bearish55Method 4
2026-09-09 · retrospective45Neutral52Method 4
2026-09-0444Bearish70Method 4
2026-09-01 · retrospective49Neutral60Method 4
2026-08-31 · retrospective49Neutral73Method 3
2026-08-2850Neutral73Method 3
2026-08-26 · retrospective51Neutral63Method 3
2026-08-24 · retrospective51Neutral73Method 3
2026-08-20 · retrospective53Neutral73Method 3
2026-08-19 · retrospective52Neutral73Method 3
2026-08-1458Neutral73Method 2
2026-08-1355Neutral71Method 1
2026-08-0754Neutral71Method 1
2026-08-0654Neutral70Method 1
2026-08-0445Neutral60Method 1
2026-07-3152Neutral78Method 1
2026-07-2350Neutral54Method 1

Specialists

8 of 10 published specialist analyses are available.

Each specialist’s view is shown as the published research recorded it; supporting detail appears only when it was recorded with that same view.

2 unavailable

ABT research

Financial specialist

Showing Financial specialist result.

Financial specialist

Evaluated for this session

Neutral

Abbott converts 1.18 of net income into free cash flow on $7,378 million trailing-twelve-month free cash flow, with a 17.1% operating margin matching the 17.1% sector operating-margin median and 6.6% revenue growth above the 4.6% sector revenue-growth median.

Full analyst note

What the specialist sees

Evidence: trailing-twelve-month revenue was $45,134 million with 6.6% growth, trailing-twelve-month free cash flow was $7,378 million at 1.18 conversion, and the facts' period ends 2026-03-31 predate the 10-Q filed on 2026-07-28.

Why it matters now

Steady mid-single-digit revenue growth with a 17.1% operating margin and 1.18 free cash flow conversion supports durable cash generation, though the newest quarter's margin step-down is a caution.

What could change the view

Countercase: The 10-Q filed on 2026-07-28 is not yet reflected in these facts, and the 12.0% operating margin in the newest quarter is a sharp step down. Falsifier: A later reading showing trailing-twelve-month free cash flow conversion below the 1.17 sector free-cash-flow-conversion median would break the cash-quality claim.

Specialist score details
Specialist score
51
Evidence confidence
70
Base weight for this role
0.13
Base weight × confidence
9.10
Weight in the score (the chip's weight)
0.18
Weighted contribution
9.39
Business driver
Abbott converts 1.18 of net income into free cash flow on $7,378 million trailing-twelve-month free cash flow, with a 17.1% operating margin matching the 17.1% sector operating-margin median and 6.6% revenue growth above the 4.6% sector revenue-growth median.
Mechanism
Steady mid-single-digit revenue growth with a 17.1% operating margin and 1.18 free cash flow conversion supports durable cash generation, though the newest quarter's margin step-down is a caution.
Countercase
The 10-Q filed on 2026-07-28 is not yet reflected in these facts, and the 12.0% operating margin in the newest quarter is a sharp step down.
Contributions & coverage details

Specialist contributions

Each specialist’s recorded numbers, in the usual specialist order, as recorded: nothing is re-ranked or recalculated. Weights and contributions show two decimals; hover for the exact value.

Financial specialist

Neutral

Score
51
Evidence confidence
70
Weight in the score
0.18
Weighted contribution
9.39

Risk specialist

Neutral

Score
47
Evidence confidence
65
Weight in the score
0.11
Weighted contribution
4.95

Sector specialist

Bearish

Score
44
Evidence confidence
62
Weight in the score
0.13
Weighted contribution
5.52

SEC filings specialist

Neutral

Score
50
Evidence confidence
55
Weight in the score
0.03
Weighted contribution
1.67

News specialist

Neutral

Score
55
Evidence confidence
55
Weight in the score
0.12
Weighted contribution
6.74

Price-trend specialist

Neutral

Score
58
Evidence confidence
60
Weight in the score
0.24
Weighted contribution
14.09

Valuation specialist

Neutral

Score
50
Evidence confidence
30
Weight in the score
0.10
Weighted contribution
4.86

Economy specialist

Neutral

Score
54
Evidence confidence
55
Weight in the score
0.09
Weighted contribution
4.81

Published specialist analyses unavailable: Geopolitics specialist, Social-media specialist. No specialist result is inferred.

  • Geopolitics specialist: This specialist had no checked public source on this run, so no source-backed analysis is shown.
  • Social-media specialist: This specialist had no checked public source on this run, so no source-backed analysis is shown.

How this insight was formed

Each specialist view shown here is checked against the published research files. Sagehood research combined those views into the one Research Score above.

Evidence & method

Inspect the reasoning, source records and valuation behind this dated view.

Sagehood research reasoningSpecialist reasoning, selected statements and filing context
Accepted publication2026-10-30 researchNext eligible session 2026-11-02point-in-time

ABT: Sagehood research reasoning

Accepted research score

52

Neutral50 is balanced
Lead specialist in the research decision:

Financial specialist

Neutral

Specialist score 51Evidence confidence 70
What the specialist sees

Abbott converts 1.18 of net income into free cash flow on $7,378 million trailing-twelve-month free cash flow, with a 17.1% operating margin matching the 17.1% sector operating-margin median and 6.6% revenue growth above the 4.6% sector revenue-growth median.

Why it matters

Steady mid-single-digit revenue growth with a 17.1% operating margin and 1.18 free cash flow conversion supports durable cash generation, though the newest quarter's margin step-down is a caution.

What argues against it

The 10-Q filed on 2026-07-28 is not yet reflected in these facts, and the 12.0% operating margin in the newest quarter is a sharp step down.

This specialist’s break condition: A later reading showing trailing-twelve-month free cash flow conversion below the 1.17 sector free-cash-flow-conversion median would break the cash-quality claim.

How the score was formed

The specialists’ weighted starting point was 52.03. Sagehood research’s adjustment was −0.03. 52 on 2026-10-29 → 52 on 2026-10-30 (0 points). This is simple arithmetic between the two published scores, not an explanation of the change.

Evidence Sagehood research weighed

These selected claims are evidence Sagehood research weighed, not a reconstruction of the numeric adjustment.

Claims as this research published them. Sagehood confirms each claim and its support were published together with this research. That is not an independent check, and it does not prove the claim is accurate or predict future performance.

  1. Financial specialist

    Same statement as under “What the specialist sees” above.

  2. Risk specialist

    One elevated axis: drawdown now of −16.7% sits in the 15-25% band, while 20-day annualized volatility of 22.8% is near the 60-day 21.5% and downside beta of 0.18 is below beta to SPY of −0.02.

  3. Price-trend specialist

    90-day log-channel +19.6%/yr, +5.7% over 200-day average; holding $104.82 support (3 touches); wave-2 pullback in primary impulse; 14-week RSI 54.7; view breaks below $100.10.

Sagehood research decision

The investment case, main risk and break condition are the ones shown under Sagehood’s view at the top of this page.

Recorded break condition
Break condition as kept in the decision trail

A later reading showing TTM free cash flow conversion below the 1.17 sector free-cash-flow-conversion median would break the cash-quality claim.

Evidence & sourcesClaim-support availability, filing-context links and research method

ABT: This run has no checked links from its claims to their evidence. The specialists’ writing is shown as recorded, and no missing evidence is filled in.

Accepted research

Research dated 2026-10-30.

How this research was made

This research is AI-generated and is not investment advice.

Research date
2026-10-30
Valuation & peersInput limits notedFair-value cells, peer multiples and the inputs behind the range

Valuation the research computed

Against the 2026-10-30 close of $106.20 (recorded)

Fundamentals reference date: 2026-03-31 · a newer 10-Q (filed 2026-07-28) is on record; some figures here may predate it.

No fair-value range this session: the cash-flow valuation grid was unavailable because free cash flow or share data was missing

Multiples against the peer group

Health Care · 7 companies in the group

  • Price to earnings (trailing twelve months)Not computed in this research

    Peer median 23.78× · middle half 17.00× to 40.16×

  • Price to salesNot computed in this research

    Peer median 2.99× · middle half 2.66× to 4.42×

  • Price to bookNot computed in this research

    Peer median 2.52× · middle half 2.26× to 7.13×

  • Free cash flow yieldNot computed in this research

    Peer median 5.78% · middle half 4.64% to 6.77%

This run declares Enterprise value to EBITDA and computes no value for it, for this company or for its peer group.

Evidence limits: 17 valuation inputs required conservative handling: the filing date could not be independently verified; another valuation input required conservative handling; diluted earnings per share was unavailable; no full-year gross-profit line was filed; no full-year diluted share count was filed; no full-year shares-outstanding figure was filed; depreciation and amortization were available but not used because this version does not compute an EV/EBITDA multiple; debt coverage was incomplete; the measured beta of 0.09 was below the floor used for the cost of equity, so the floor was applied instead; the cash-flow valuation grid was unavailable because free cash flow or share data was missing.

Includes the currently displayed specialist or comparison, not every specialist. Dates and limitations remain attached.

Sagehood research is for general information. It is not individualized investment advice or a recommendation to buy or sell any security.

Abbott Laboratories (ABT) research | Sagehood